Mike Ouimette Sells 13,270 Shares of Pliant Therapeutics, Inc. (NASDAQ:PLRX) Stock

Pliant Therapeutics, Inc. (NASDAQ:PLRX) General Counsel Mike Ouimette sold 13,270 shares of the stock in a transaction that occurred on Friday, January 17th. The stock was sold at an average price of $11.20, for a total transaction of $148,624.00. Following the transaction, the general counsel now owns 80,774 shares in the company, valued at approximately $904,668.80. The trade was a 14.11 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Mike Ouimette also recently made the following trade(s):

• On Wednesday, January 22nd, Mike Ouimette sold 10,230 shares of Pliant Therapeutics stock. The shares were sold at an average price of $10.99, for a total transaction of $112,427.70.

Pliant Therapeutics Trading Down 2.0 %

Shares of PLRX stock opened at $10.92 on Friday. Pliant Therapeutics, Inc. has a fifty-two week low of $10.22 and a fifty-two week high of $18.92. The stock’s fifty day moving average price is $13.14 and its two-hundred day moving average price is $13.05. The company has a debt-to-equity ratio of 0.09, a quick ratio of 10.26 and a current ratio of 10.26. The company has a market cap of $664.48 million, a PE ratio of -3.27 and a beta of 1.05.

Pliant Therapeutics (NASDAQ:PLRX) last released its earnings results on Thursday, November 7th. The company reported ($0.95) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.99) by $0.04. Equities analysts predict that Pliant Therapeutics, Inc. will post -3.65 EPS for the current fiscal year.

Institutional Investors Weigh In On Pliant Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in PLRX. Great Point Partners LLC lifted its stake in Pliant Therapeutics by 42.4% in the 2nd quarter. Great Point Partners LLC now owns 2,636,864 shares of the company’s stock valued at $28,346,000 after purchasing an additional 785,000 shares during the last quarter. State Street Corp lifted its stake in shares of Pliant Therapeutics by 1.9% in the 3rd quarter. State Street Corp now owns 1,402,730 shares of the company’s stock valued at $15,725,000 after acquiring an additional 26,610 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of Pliant Therapeutics by 2.4% during the 3rd quarter. Geode Capital Management LLC now owns 1,318,308 shares of the company’s stock valued at $14,781,000 after acquiring an additional 31,221 shares in the last quarter. Franklin Resources Inc. grew its position in Pliant Therapeutics by 1.5% during the 3rd quarter. Franklin Resources Inc. now owns 1,039,904 shares of the company’s stock worth $11,657,000 after acquiring an additional 14,913 shares during the last quarter. Finally, Fernwood Investment Management LLC grew its position in Pliant Therapeutics by 3.4% during the 3rd quarter. Fernwood Investment Management LLC now owns 513,136 shares of the company’s stock worth $5,752,000 after acquiring an additional 16,850 shares during the last quarter. 97.30% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a “buy” rating and set a $38.00 target price on shares of Pliant Therapeutics in a research report on Friday, November 8th. Seven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $40.50.

Pliant Therapeutics Company Profile

Pliant Therapeutics, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis.